Renaissance Capital logo

OptiNose Priced, Nasdaq: OPTN

Commercializing a drug-device nasal spray for chronic rhinosinusitis.

Industry: Health Care

First Day Return: +18.8%

Industry: Health Care

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. Our lead product, XHANCE, is a therapeutic utilizing our proprietary Breath Powered exhalation delivery system, or EDS, that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. Chronic rhinosinusitis is a serious nasal inflammatory disease that is currently treated using therapies, such as intranasal steroids, or INS, that have significant limitations. We believe XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by current INS. We also believe that payors will respond favorably to XHANCE's clinical, cost and quality-of-care profile, as compared to current and potential future costly drug therapy and surgical treatment options. On September 18, 2017, the U.S. Food and Drug Administration, or FDA, approved our new drug application, or NDA, for XHANCE for the treatment of nasal polyps in adults. We expect to launch XHANCE in the second quarter of 2018.
more less
IPO Data
IPO File Date 09/18/2017
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.5
Deal Size ($mm) $120
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/12/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $120
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Yardley, PA, United States
Founded 2010
Employees at IPO 37
Website www.optinose.com

OptiNose (OPTN) Performance